Solid Biosciences Inc. SLDB

SLDB Company Overview

Solid Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, with a primary emphasis on Duchenne muscular dystrophy (DMD). The company operates within the biotechnology and gene therapy industries and develops adeno-associated virus (AAV)-based gene therapies, genetic payload technologies, and delivery platforms intended to address severe rare diseases with high unmet medical need. Its principal revenue drivers historically have consisted of collaboration revenue, licensing arrangements, and financing activities, as the company has not yet commercialized a product based on publicly available filings.

The company’s core programs include SGT-003, a next-generation gene therapy candidate for DMD, and a broader pipeline targeting cardiac and neuromuscular indications through genomic medicine approaches. Solid Biosciences was founded in 2013 by families affected by Duchenne muscular dystrophy and has evolved from an early-stage rare disease startup into a publicly traded biotechnology company listed on Nasdaq under the ticker SLDB. The company has positioned itself around differentiated AAV capsid engineering, targeted delivery technologies, and integrated genomic medicine capabilities designed to improve tissue targeting, durability, and safety profiles relative to earlier-generation gene therapies.